04 Apr, EOD - Indian

SENSEX 75364.69 (-1.22)

Nifty 50 22904.45 (-1.49)

Nifty Bank 51502.7 (-0.18)

Nifty IT 33511.4 (-3.58)

Nifty Midcap 100 50645.95 (-2.91)

Nifty Next 50 61468.7 (-2.59)

Nifty Pharma 20560 (-4.03)

Nifty Smallcap 100 15675.95 (-3.56)

04 Apr, EOD - Global

NIKKEI 225 33780.58 (-2.75)

HANG SENG 22849.81 (-1.52)

S&P 5122.25 (-5.92)


Hot Pursuit News

You are Here : Home > News > Hot Pursuit News >

(06 Mar 2024, 12:19)

Sakar Healthcare soars after oncology unit receives EU GMP approval

Sakar Healthcare surged 8.49% to Rs 408.95 after the company's oncology unit has attained EU GMP approval valid for three years from the audit date of 5th March 2024.


Sakar Healthcare announced today that its oncology unit located in Bavla, Gujarat, has received a three-year European Union Good Manufacturing Practice (EU GMP) approval. This certification signifies that the unit meets the strictest international standards for manufacturing quality pharmaceuticals.

The facility boasts advanced equipment capable of producing a wide range of research-driven oncology formulations, including liquid injections, lyophilized injections, tablets, capsules, and granules. The European Agency audit team conducted a thorough inspection in late 2023, ultimately granting approval for both oral solid dosage and injection products.

This achievement builds upon Sakar Healthcare's existing WHO GMP certification, which has allowed the company to successfully manufacture and sell oncology products within India. Notably, the company has developed 30 generic anti-cancer molecules and efficiently transferred the technology to its manufacturing units.

Further, Sakar Healthcare has made significant strides in regulatory compliance. The company has prepared Common Technical Documents (CTD) dossiers, conducted bioequivalence studies, completed process validation, and generated stability data for both oral solid dosage forms and injections. Additionally, 11 of their oncology Active Pharmaceutical Ingredients (APIs) have received Written Confirmation for export to the European Union.

The EU GMP certification, coupled with Sakar Healthcare's internal preparedness, opens doors for significant export opportunities. The company is actively engaged in discussions regarding business contracts, dossier submissions, and supply agreements, with the potential to tap into the vast European market and other regulated regions. This expansion presents a chance for substantial growth and strengthens Sakar Healthcare's position in the global oncology market.

The fully integrated oncology unit offers a distinct competitive advantage through its comprehensive capabilities and streamlined production processes.

Sakar Healthcare is engaged in manufacturing of pharmaceutical products providing liquid orals, cephalosporin tablet, capsule, dry powder syrup, dry powder injections, liquid injectables (SVP) in ampoules and vials & lyophilized injections. Its products are exported worldwide.

On a consolidated basis, net profit of Sakar Healthcare declined 48.38% to Rs 2.07 crore on 11.23% increase in net sales to Rs 37.23 crore in Q3 December 2023 over Q3 December 2022.


More News
More Company News View Company Information

Capital Market Publishers India Pvt. Ltd

401, Swastik Chambers, Sion Trombay Road, Chembur, Mumbai - 400 071, India.

Formed in 1986, Capital Market Publishers India Pvt Ltd pioneered corporate databases and stock market magazine in India. Today Capitaline corporate database cover more than 35,000 listed and unlisted Indian companies. Latest technologies and standards are constantly being adopted to keep the database user-friendly, comprehensive and up-to-date.

Over the years the scope of the databases has enlarged to cover economy, sectors, mutual funds, commodities and news. Many innovative online and offline applications of these databases have been developed to meet various common as well as customized requirements.

While all the leading institutional investors use Capitaline databases, Capital Market magazine gives access to the databases to individual investors through Corporate Scoreboard. Besides stock market and company-related articles, the magazine’s independent and insightful coverage includes mutual funds, taxation, commodities and personal finance.

The power of the database is harnessed by our fired-up reporters to generate interesting ideas. The reader-friendly presentation of the idea, supplemented by relevant data and information, can be accessed online through Capita Telefolio and Telefolio Gold. These ideas are used by individual investors as well as institutional investors to do further research and stay ahead.

Copyright @ Capital Market Publishers India Pvt.Ltd

Designed, Developed and maintained by CMOTS Infotech (ISO 9001:2015 Certified)

Site best viewed in Internet Explorer Edge ,   Google Chrome 115.0.5790.111 + ,   Mozilla Firefox 115.0.3 + ,   Opera 30.0+, Safari 16.4.1 +